Tonix Pharmaceuticals Holding (TNXP) said Thursday it received a patent from the US Patent and Trademark Office for its intranasal migraine treatment, Tosymra.
The patent granted on Tuesday covers the pharmaceutical composition, treatment method, and delivery system for Tosymra, the company said. The patent is set to expire in 2030, excluding potential extensions, it added.
Shares of the company rose over 7% in recent premarket activity.
Price: 0.1565, Change: +0.01, Percent Change: +7.86
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。